Innate Immunity and the Failing Heart
Why the study?
Does antagonizing inflammatory mediators improve outcomes in patients with heart failure?
Population
Patients with heart failure, including heart failure with reduced ejection fraction, heart failure with…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Negative phase III trials support avoiding inflammatory mediator antagonism in heart failure; leaves open refined innate immunity targeting.
Structured PICO
Does antagonizing inflammatory mediators improve outcomes in patients with heart failure?
P
Population
Patients with heart failure, including heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and acute decompensated heart failure.
I
Intervention
Antagonism of inflammatory mediators
Despite experimental evidence linking inflammation to ventricular remodeling, phase III trials of anti-inflammatory therapies in heart failure have been negative, necessitating a deeper understanding of innate immunity.
Cite This Study
Douglas L. Mann (2015) studied this question.